The pharmacokinetic profiles described in earlier modules reflect adult patients with intact organ function. In clinical practice, the populations most often prescribed antipsychotics include elderly patients with reduced renal and hepatic reserve, patients with psychiatric comorbidities and organ impairment, and women of reproductive age in whom pregnancy substantially alters drug disposition. Understanding how each special population modifies the standard pharmacokinetic framework is essential for safe prescribing.

The majority of antipsychotics are extensively metabolized by hepatic cytochrome P450 (CYP) enzymes and are therefore subject to clinically meaningful pharmacokinetic changes in hepatic impairment. Reduced hepatic blood flow and decreased CYP enzyme activity in cirrhosis prolong the half-lives of most antipsychotics and increase peak plasma concentrations after oral dosing by reducing first-pass metabolism. Olanzapine, quetiapine, clozapine, aripiprazole, and risperidone all require dose reduction or slower titration in moderate to severe hepatic impairment (Child-Pugh Class B or C).¹ Paliperidone is the exception among commonly used second-generation antipsychotics (SGAs): because it is renally cleared with minimal hepatic metabolism, its dosing is largely unaffected by hepatic impairment and it may be preferred in patients with significant liver disease. Haloperidol and other first-generation antipsychotics (FGAs) are similarly subject to impaired hepatic clearance in liver disease, with increased risk of extrapyramidal side effects (EPS) at standard doses due to elevated plasma levels.

Most antipsychotics undergo negligible renal clearance of the parent drug and are therefore relatively unaffected by reduced glomerular filtration rate (GFR) in terms of the parent compound's pharmacokinetics. The principal exception is paliperidone, which is approximately 59% renally excreted as unchanged drug; dose reduction is required when creatinine clearance falls below 80 mL/min, with substantial reductions at creatinine clearance below 50 mL/min and further adjustment below 10 mL/min where paliperidone is not recommended for use without specialist guidance.¹ Active metabolites of some antipsychotics may accumulate in renal impairment even when the parent drug is hepatically cleared; 9-hydroxyrisperidone (the active metabolite of risperidone that is identical to paliperidone) is renally excreted and therefore accumulates in renal insufficiency, warranting risperidone dose reduction in proportion to GFR decline. Patients on dialysis represent an extreme case; most antipsychotics are highly protein-bound and have large volumes of distribution, making them poorly dialyzable, so standard dosing principles generally apply with close clinical monitoring rather than supplemental post-dialysis dosing.

Elderly patients require systematically lower antipsychotic doses for several converging reasons: reduced hepatic CYP enzyme activity prolongs half-lives and increases plasma levels; reduced renal clearance accumulates renally excreted metabolites; decreased plasma protein binding (reduced albumin) increases the free fraction of highly protein-bound antipsychotics; reduced volume of distribution increases plasma concentrations; and reduced baseline nigrostriatal dopamine (DA) reserve substantially lowers the threshold for drug-induced parkinsonism (DIP). The pharmacodynamic sensitivity to anticholinergic adverse effects (cognitive impairment, urinary retention, constipation), orthostatic hypotension (fall and fracture risk), and QTc prolongation is also substantially increased in elderly patients compared with younger adults.² As a practical consequence, dose initiation in elderly patients should begin at 25 to 50% of the standard adult starting dose and titration should proceed more slowly. Quetiapine at low doses is commonly chosen in elderly patients for its low EPS and negligible DIP risk; clozapine, while highly effective for treatment-resistant conditions, carries disproportionate risks in the elderly due to orthostatic hypotension, sedation, and cognitive impairment from its anticholinergic and H1 blocking properties.

A specific and consequential concern in elderly patients is the use of antipsychotics for behavioral and psychological symptoms of dementia (BPSD). All antipsychotics carry a Food and Drug Administration (FDA) black-box warning for increased mortality in elderly patients with dementia-related psychosis, based on meta-analyses showing an approximately 1.6 to 1.7-fold increase in all-cause mortality (predominantly cardiovascular and infectious causes) compared with placebo in this population.³ This warning applies to both FGAs and SGAs. The appropriate clinical response is not to never use antipsychotics in dementia but to use them only after non-pharmacological interventions have been exhausted, at the lowest effective dose, for the shortest duration necessary, with documented informed consent from the patient or surrogate, and with regular reassessment of continued need. Quetiapine is most commonly used in this context despite limited evidence for efficacy in BPSD, primarily because of its tolerability profile.

The management of psychiatric illness during pregnancy requires balancing the risks of antipsychotic exposure to the fetus against the substantial risks of untreated maternal psychosis, which include preterm birth, low birth weight, poor prenatal care adherence, and risk of postpartum psychosis. No antipsychotic is categorically contraindicated in pregnancy, and for most women with schizophrenia or bipolar disorder, continuation of effective antipsychotic treatment during pregnancy is the appropriate clinical decision.⁴ The available data, primarily from registries and observational studies, do not demonstrate a consistent pattern of major fetal malformations attributable to antipsychotics as a class. Neonatal adaptation syndrome, characterized by extrapyramidal symptoms, sedation, feeding difficulties, and respiratory distress in newborns exposed to antipsychotics during the third trimester, is a documented risk requiring neonatal monitoring at delivery. Haloperidol has the most extensive historical safety data in pregnancy among antipsychotics. Among SGAs, quetiapine and olanzapine have the largest pregnancy exposure registries. Clozapine exposure in pregnancy is associated with neonatal seizures and requires extra vigilance. Gestational diabetes risk is increased with metabolically active agents (clozapine, olanzapine), which demands glucose monitoring throughout pregnancy. Regarding lactation, most antipsychotics are excreted in breast milk, though infant exposure levels are generally low; haloperidol, quetiapine, and olanzapine have the most data supporting relative safety in breastfeeding with careful infant monitoring.

Antipsychotic use in pediatric populations is governed by a limited set of approved indications. FDA-approved pediatric indications include schizophrenia (aripiprazole, quetiapine, paliperidone, risperidone from age 13; olanzapine from age 13; clozapine for treatment-resistant schizophrenia in adolescents); bipolar I mania (aripiprazole from age 10; quetiapine from age 10; risperidone from age 10; olanzapine from age 13); irritability associated with autistic disorder (aripiprazole from age 6; risperidone from age 5); and Tourette syndrome (aripiprazole from age 6). Children and adolescents are more sensitive than adults to antipsychotic-induced weight gain and metabolic effects, and metabolic monitoring in pediatric patients should follow the same schedule as adults, with particular attention given the longer time horizon of exposure. Prolactin elevation is clinically significant in adolescent females given its effects on pubertal development and bone density accumulation during a critical window.¹

Treatment-resistant schizophrenia (TRS) is defined by failure to achieve adequate symptom control despite two adequate trials of antipsychotics at adequate doses for adequate durations. The most widely used operational definition requires failure of at least two antipsychotics from different chemical classes at doses equivalent to at least 600 mg per day of chlorpromazine equivalents for at least 6 weeks each, with confirmed medication adherence.⁶ Approximately 20 to 30% of patients with schizophrenia meet criteria for TRS, and a significant proportion of these patients have been inadequately treated for years before the diagnosis is formally recognized and clozapine initiated. The delay between the emergence of TRS and clozapine initiation has been repeatedly documented as excessive in clinical practice, with median times of 4 to 9 years reported in large registry studies, representing a substantial and preventable period of unnecessary morbidity.

Clozapine is the only antipsychotic with demonstrated superior efficacy in TRS, and no other agent, strategy, or augmentation has been shown to match clozapine's response rates in this population. The response rate to clozapine in confirmed TRS is approximately 30 to 60% depending on the definition of response used, compared with near-zero rates to further trials of standard antipsychotics. Clozapine should be initiated after the second antipsychotic trial failure, not as a last resort after exhausting all other options. Delays beyond this point expose patients to continued psychosis, progressive functional decline, and the ongoing risks of other antipsychotics without the potential benefit of the one agent with established superiority in their condition.⁶ Plasma clozapine level monitoring (target 350 to 600 ng/mL) is recommended to confirm therapeutic exposure before declaring clozapine failure; apparent non-response at a plasma level below 350 ng/mL represents inadequate dosing rather than true TRS to clozapine.

When clozapine at therapeutic plasma levels produces partial but incomplete response, augmentation strategies are employed, though the evidence base for most is limited. The most studied augmentation is the addition of a second antipsychotic, most commonly amisulpride or aripiprazole, to clozapine. Amisulpride augmentation of clozapine has the strongest evidence base for true TRS partial responders, based on small randomized trials showing incremental improvement in positive symptoms; the combination requires attention to additive QTc risk (amisulpride carries meaningful QTc liability) and metabolic monitoring. Aripiprazole augmentation of clozapine produces metabolic benefits (weight reduction, improved glucose and lipid profiles) and may provide modest additional antipsychotic effect through complementary receptor mechanisms, though evidence for the latter is weaker than for the metabolic benefit.⁷ Mood stabilizers, particularly valproate, are frequently added to clozapine regimens for seizure prophylaxis (at doses above 600 mg per day), mood stabilization in schizoaffective disorder, or behavioral aggression, and their addition does not require dose adjustment of clozapine. Lamotrigine augmentation of clozapine has some randomized trial evidence for improvement in negative and cognitive symptoms in partial clozapine responders, though effects are modest.

A subset of patients fails to respond adequately even to therapeutic clozapine, a condition sometimes termed ultra-treatment-resistant schizophrenia or clozapine-resistant schizophrenia. This group presents a significant therapeutic challenge with no clearly superior pharmacological solution. Electroconvulsive therapy (ECT) combined with clozapine has the most evidence in this population, with several case series and small trials demonstrating clinically meaningful improvement in patients who had not responded to clozapine alone. The mechanisms are incompletely understood but may involve ECT-mediated enhancement of DA and serotonin neurotransmission that complements clozapine's receptor profile. High-dose antipsychotic strategies, once common, have not been shown to benefit true TRS and substantially increase adverse effect burden; they are not recommended in current guidelines.

Negative symptoms encompass five domains: blunted affect, alogia (poverty of speech), avolition (lack of motivation), anhedonia, and asociality. They are among the strongest predictors of long-term functional outcome in schizophrenia, more so than positive symptoms, and they remain substantially undertreated because the pharmacological options are more limited and the response to available treatments is more modest than for positive symptoms. Negative symptoms may be primary, arising from the intrinsic pathophysiology of schizophrenia and reflecting mesocortical dopamine (DA) deficiency and glutamatergic dysfunction, or secondary to other treatable conditions: extrapyramidal side effects (EPS) producing akinesia and flattened affect that mimics primary negative symptoms, depression co-occurring with schizophrenia (post-psychotic depression or a primary depressive episode), inadequately treated positive symptoms driving social withdrawal, or the direct pharmacological effect of excessive D2 blockade reducing hedonic capacity. The clinical first step in addressing prominent negative symptoms is to exclude secondary causes, because treating EPS, depression, or over-medication is more effective than adding a negative-symptom-targeted pharmacological agent to an unchanged regimen.

For primary negative symptoms, cariprazine has the strongest pharmacological evidence base as discussed in Module 4, based on the Nemeth et al. 2017 Lancet trial demonstrating superiority over risperidone in a 26-week randomized controlled trial (RCT) designed with predominant negative symptoms as the primary endpoint.¹⁰ Lurasidone shows secondary benefits on negative symptom scales in schizophrenia trials, likely through its 5-HT7 antagonism promoting prefrontal cortex (PFC) DA tone. No currently approved antipsychotic other than cariprazine has Class I evidence from a trial specifically powered for a primary negative symptom endpoint. Beyond pharmacology, the most evidence-based interventions for negative symptoms are psychosocial: Individual Placement and Support (IPS) model supported employment has the strongest evidence for improving vocational functioning in patients with significant negative symptoms; social skills training produces modest improvements in social functioning; and cognitive remediation improves neuropsychological performance that underlies some functional deficits.

Rapid tranquilization refers to the pharmacological management of acute agitation in the context of psychotic illness, aiming for sufficient behavioral calming to ensure safety without excessive sedation that prevents clinical assessment or creates respiratory risk. The preferred agents and routes differ by clinical context. IM haloperidol 5 mg plus IM lorazepam 2 mg is the most widely used combination in emergency settings and has decades of clinical experience supporting its efficacy and safety in adults without significant cardiac or respiratory comorbidity. IM olanzapine 10 mg is an effective alternative with lower EPS risk than haloperidol; it must not be administered concurrently with IM or IV benzodiazepines in the same session due to the documented risk of severe respiratory depression and deaths reported with this specific combination.¹

IM ziprasidone 10 to 20 mg is an option with minimal EPS but requires prior ECG assessment to confirm absence of QTc prolongation. Inhaled loxapine (Adasuve) is an approved inhaled antipsychotic for acute agitation in schizophrenia and bipolar disorder, with rapid onset (approximately 10 minutes) through pulmonary delivery, though bronchospasm risk in patients with asthma or chronic obstructive pulmonary disease (COPD) limits its use and it is restricted to settings where bronchospasm management is available.¹¹ Oral or sublingual agents (dissolving olanzapine, risperidone solution) are appropriate for patients who are agitated but cooperative with oral medication.